Page 2 - Accoya News Today

Coya Therapeutics’ (NASDAQ:COYA – Get Rating) lock-up period will end on Tuesday, June 27th. Coya Therapeutics had issued 3,050,000 shares in its IPO on December 29th. The total size of the offering was $15,250,000 based on an initial share price of $5.00. Shares of the company owned by major shareholders and company insiders will be […]

Coya Therapeutics, Inc. (NASDAQ:COYA – Get Rating) was the recipient of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 44,200 shares, an increase of 65.5% from the May 15th total of 26,700 shares. Currently, 0.6% of the company’s shares are short sold. Based […]

Coya Therapeutics, Inc. (NASDAQ:COYA – Get Rating) was the target of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 44,200 shares, a growth of 65.5% from the May 15th total of 26,700 shares. Currently, 0.6% of the company’s shares are sold short. Based […]

Coya Therapeutics (NASDAQ:COYA – Get Rating) had its target price raised by Chardan Capital from $9.00 to $11.00 in a research report released on Wednesday morning, The Fly reports. Separately, BTIG Research began coverage on Coya Therapeutics in a research note on Thursday, May 18th. They set a buy rating on the stock. Coya Therapeutics […]

Houston, TX, June 8, 2023 - (ACN Newswire) - Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic programs intended to

Coya Therapeutics (NASDAQ:COYA – Get Rating) had its price objective boosted by equities researchers at Chardan Capital from $9.00 to $11.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Chardan Capital’s target price would indicate a potential upside of 134.04% from the stock’s current price. Separately, BTIG Research started […]

Coya Therapeutics, Inc. (NASDAQ:COYA – Get Rating)’s share price was up 1.1% on Monday . The stock traded as high as $5.49 and last traded at $5.30. Approximately 41,781 shares were traded during trading, an increase of 70% from the average daily volume of 24,617 shares. The stock had previously closed at $5.24. Analyst Ratings […]

HOUSTON, TX / ACCESSWIRE / April 14, 2023 / In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear

Coya Therapeutics (NASDAQ:COYA – Get Rating)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a research report issued on Thursday, Benzinga reports. They presently have a $9.00 price target on the stock. Chardan Capital’s price target indicates a potential upside of 125.56% from the company’s previous close. Coya Therapeutics Trading […]

Chardan Capital restated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA – Get Rating) in a research report sent to investors on Wednesday, Benzinga reports. They currently have a $9.00 price target on the stock. Coya Therapeutics Stock Up 0.9 % Shares of COYA opened at $4.06 on Wednesday. The business’s 50-day simple moving […]